| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst Susan Anderson downgrades Kenvue (NYSE:KVUE) from Buy to Hold and lowers the price target from $26...
Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for ...
https://www.texasattorneygeneral.gov/news/releases/attorney-general-paxton-sues-big-pharma-manufacturers-deceptively-marketing-...
Jefferies analyst Keith Devas maintains Kenvue (NYSE:KVUE) with a Buy and lowers the price target from $25 to $23.
https://truthsocial.com/@realDonaldTrump/115442316583935494
-CNBC Interview